SPRY
BEARISH
$8.18
Live
ARS Pharmaceuticals, Inc. · NASDAQ
Target $26.71
(+226.6%)
$6.66
52W Range
$18.9
At a glance
Key valuation, profitability, growth, and risk metrics.
Updated Apr 20, 2026
Market cap
$812.25M
P/E
N/A
ROE
-92.3%
Profit margin
-203.3%
Debt/Equity
1.47
Dividend yield
N/A
AI Analysis
AI-powered fundamental assessment
Confidence
85%
SPRY exhibits severe financial distress as evidenced by a critical Piotroski F-Score of 1/9, indicating a near-total failure of fundamental health metrics. Despite a strong liquidity position (Current Ratio 7.28), the company is facing a catastrophic revenue collapse of -67.60% YoY and deep negative profit margins of -203.25%. There is a stark divergence between the 'Strong Buy' analyst consensus and the actual data, which shows bearish insider selling and a 0/100 technical trend. The valuation remains speculative and disconnected from current operational performance.
Key Strengths
Very high current ratio (7.28) providing a short-term liquidity cushion
Strong quick ratio (6.93) indicating minimal reliance on inventory for liquidity
Positive gross margin (60.13%) suggesting a viable core product price point
Strong analyst support with a high target price of $26.71
Recent Q/Q EPS growth improvement (+19.2%)
Key Risks
Severe revenue contraction (-67.60% YoY)
Critical Piotroski F-Score (1/9) signaling fundamental weakness
Deeply negative profitability (Profit Margin -203.25%)
Bearish insider activity with $1.67M in recent sales
High Price-to-Sales (9.64) and Price-to-Book (7.11) ratios relative to growth
Performance Snowflake
Multi-dimensional analysis across 5 key categories
Overall
15
Weak
15
10
20
30
0
AI Verdict
High Risk / Speculative
Key drivers: Piotroski F-Score 1/9, Revenue collapse, Insider selling, Technical breakdown
Confidence
90%
Value
15/100
Ref P/E, PEG, Graham Number
Positives
No standout positives identified.
Watchpoints
- P/S of 9.64 is excessive for shrinking revenue
- P/B of 7.11 indicates high premium over book value
- No Graham Number due to negative earnings
Future
10/100
Ref Growth rates
Positives
- Analyst target price suggests high future expectations
Watchpoints
- YoY Revenue Growth -67.60%
- Q/Q Revenue Growth -67.56%
Past
20/100
Ref Historical trends
Positives
- Occasional earnings beats in previous quarters
Watchpoints
- 1Y Price Change -45%
- 5Y Price Change -78.3%
Health
30/100
Ref Altman Z-Score, Piotroski F-Score
Positives
- Excellent Current and Quick ratios
Watchpoints
- Piotroski F-Score 1/9
- Debt/Equity of 1.47
- Negative ROE and ROA
Dividend
0/100
Ref Yield, Payout
Positives
No standout positives identified.
Watchpoints
- No dividend paid
- 0/100 dividend strength
Stock Price & Analyst Targets
Real-time price movements and analyst price targets
Current Price
$8.18
Analyst Target
$26.71
Upside/Downside
+226.6%
Multi-Horizon Performance vs Peers
Price momentum across 5Y → 1W horizons for SPRY and closest competitors.
Updated 2026-04-17
| Company | 5Y | 3Y | 1Y | 6M | 1M | 1W |
|---|---|---|---|---|---|---|
|
SPRY
ARS Pharmaceuticals, Inc.
Primary
|
-78.3% | +19.2% | -45.0% | -18.6% | -1.4% | +1.6% |
|
AMPH
Amphastar Pharmaceuticals, Inc.
Peer
|
-5.1% | -51.1% | -30.7% | -35.2% | -36.4% | -6.0% |
|
AMN
AMN Healthcare Services, Inc.
Peer
|
-72.8% | -78.8% | -26.3% | +3.5% | +28.0% | +7.7% |
|
MGTX
MeiraGTx Holdings plc
Peer
|
-29.7% | +81.4% | +75.7% | +23.0% | +30.3% | +1.2% |
|
ARVN
Arvinas, Inc.
Peer
|
-84.3% | -57.8% | +42.5% | +57.4% | -7.0% | -10.4% |
SPR
ARS Pharmaceuticals, Inc.
Primary
5Y
-78.3%
3Y
+19.2%
1Y
-45.0%
6M
-18.6%
1M
-1.4%
1W
+1.6%
AMP
Amphastar Pharmaceuticals, Inc.
Peer
5Y
-5.1%
3Y
-51.1%
1Y
-30.7%
6M
-35.2%
1M
-36.4%
1W
-6.0%
AMN
AMN Healthcare Services, Inc.
Peer
5Y
-72.8%
3Y
-78.8%
1Y
-26.3%
6M
+3.5%
1M
+28.0%
1W
+7.7%
MGT
MeiraGTx Holdings plc
Peer
5Y
-29.7%
3Y
+81.4%
1Y
+75.7%
6M
+23.0%
1M
+30.3%
1W
+1.2%
ARV
Arvinas, Inc.
Peer
5Y
-84.3%
3Y
-57.8%
1Y
+42.5%
6M
+57.4%
1M
-7.0%
1W
-10.4%
Positive values indicate cumulative gains over the specified period. Comparables pulled from the same sector to highlight whether momentum is stock-specific or industry-wide.
Historical Performance Trends
Long-term financial metrics and growth patterns
Revenue & Net Income
Profit & Operating Margins
Return on Equity (ROE)
Quarterly Revenue Growth
Historical data shows last 12 quarters (3 years)
Valuation Metrics
Key valuation ratios and pricing indicators
P/E Ratio
N/A
Forward P/E
-10.8
PEG Ratio
N/A
P/B Ratio
7.11
P/S Ratio
9.64
EV/Revenue
8.73
EV/EBITDA
-4.13
Market Cap
$812.25M
Profitability
Profit margins and return metrics
Profit Margin
-203.25%
Operating Margin
-147.63%
Gross Margin
60.13%
ROE
-92.33%
ROA
-33.05%
Growth
Revenue and earnings growth rates
Revenue Growth
-67.6%
Earnings Growth
N/A
Q/Q Revenue Growth
-67.56%
Q/Q Earnings Growth
N/A
Financial Health
Balance sheet strength and liquidity metrics
Debt/Equity
1.47
Moderate
Current Ratio
7.28
Strong
Quick Ratio
6.93
Excellent
Cash/Share
$2.47
Financial Statement Flow
Interactive flow visualization showing how money moves through the company Q4 2025
Revenue
$0.0B
Gross Margin
78.1%
Op. Margin
-147.6%
Net Margin
-147.1%
Total Assets
$0.3B
Liabilities
$0.2B
Equity
$0.1B
Debt/Equity
1.87x
Operating CF
$-0.0B
Free Cash Flow
$-0.0B
FCF Yield
100%
Quarterly Earnings History
EPS performance vs analyst estimates
2026-05-14
$N/A
2026-03-09
$-0.42
+12.5% surprise
2025-11-10
$-0.52
-6.1% surprise
2025-08-13
$-0.46
+10.7% surprise
Healthcare Sector Comparison
Comparing SPRY against 470 companies in the Healthcare sector
(26 bullish, 143 neutral, 301 bearish)
Return on Equity (ROE)
-92.33%
This Stock
vs
-97.91%
Sector Avg
-5.7%
(Below Avg)
Profit Margin
-203.25%
This Stock
vs
-16.16%
Sector Avg
+1157.6%
(Superior)
Debt to Equity
1.47
This Stock
vs
3.0
Sector Avg
-50.8%
(Less Debt)
Revenue Growth
-67.6%
This Stock
vs
142.9%
Sector Avg
-147.3%
(Slower)
Current Ratio
7.28
This Stock
vs
4.65
Sector Avg
+56.5%
(Stronger)
Similar Companies
Peer comparison within the same industry
| Company | AI Rating | Market Cap | P/E | ROE | Profit Margin | Price | |
|---|---|---|---|---|---|---|---|
|
SPRY
ARS Pharmaceuticals, Inc.
|
BEARISH | $812.25M | - | -92.3% | -203.3% | $8.18 | |
|
AMPH
Amphastar Pharmaceuticals, Inc.
|
BEARISH | $835.41M | 8.96 | 12.9% | 13.6% | $18.18 | Compare |
|
AMN
AMN Healthcare Services, Inc.
|
BEARISH | $787.1M | - | -35.9% | -10.1% | $20.49 | Compare |
|
MGTX
MeiraGTx Holdings plc
|
NEUTRAL | $784.33M | - | -368.2% | -140.3% | $9.63 | Compare |
|
ARVN
Arvinas, Inc.
|
BEARISH | $782.25M | - | -16.2% | -30.8% | $12.18 | Compare |
SPRY
ARS Pharmaceuticals, Inc.
BEARISH
Mkt Cap
$812M
P/E
-
ROE
-92.3%
Price
$8.18
Recent Insider Trading
Insider buy and sell transactions from the last 6 months
| Date | Insider | Position | Transaction | Shares | Value |
|---|---|---|---|---|---|
| 2025-11-13 | DORSEY BRIAN T | Chief Operating Officer | Sale | 21,828 | $190,050 |
| 2025-11-13 | DORSEY BRIAN T | Chief Operating Officer | Option Exercise | 21,828 | $13,970 |
| 2025-11-12 | SHAH PRATIK | Director | Gift | 350,000 | - |
| 2025-11-12 | CHAKMA JUSTIN | Officer | Sale | 166,380 | $1,476,147 |
| 2025-11-12 | CHAKMA JUSTIN | Officer | Option Exercise | 30,000 | $25,200 |
DORSEY BRIAN T
Chief Operating Officer
2025-11-13
21,828 shares
·
$190,050
DORSEY BRIAN T
Chief Operating Officer
2025-11-13
21,828 shares
·
$13,970
SHAH PRATIK
Director
2025-11-12
350,000 shares
CHAKMA JUSTIN
Officer
2025-11-12
166,380 shares
·
$1,476,147
CHAKMA JUSTIN
Officer
2025-11-12
30,000 shares
·
$25,200
Insider transactions can signal confidence or concerns about company prospects
SEC Filings
Recent regulatory filings from the SEC EDGAR database
10-K
8-K
10-Q
8-K
10-Q
8-K
10-Q
Data sourced from SEC EDGAR. AI summaries generated automatically.
Past News Coverage
Recent headlines mentioning SPRY from our newsroom.
Newest → oldest
No matching news yet.